MINUTES OF GRIEVANCES MEETING

MAYO HOSPITAL LAHORE

Participants:

1.	**Prof. Dr. Nasir Chaudhary** *Head of Ophthalmology Department Unit-II Mayo Hospital Lahore*	**Chairman**
2.	**Dr. Umar Nazir** *Assistant Professor of Plastic Surgery Mayo Hospital Lahore*	**Member**
3.	**Dr. Sana Farooq** *Senior Registrar Neurology Department Mayo Hospital Lahore*	**Member**
4.	**Mr. Azeem Butt** *Deputy Drugs Controller Mayo Hospital Lahore*	**Member**
5.	**Mr. Muhammad Jawad Bhatti** *Deputy Drugs Controller Mayo Hospital Lahore*	**Member**

Proceedings:

Meeting started with the recitation from the Holy Quran. The Chairman, Grievances Committee Mayo Hospital Lahore welcomed all the participants.

ITEM NO. 01: **GRIEVANCE SUBMITTED BY M/S ONCOGEN (TENDER: CML 2024-25)**

GRIEVANCE DETAIL: The firm submitted the grievance for re-evaluation of the technical evaluation results .The firm stated that it is first vertically integrated manufacturing facility of Cancer medicines in Pakistan with Tech transfer from an FDA-certified Company. The firm is committed for positive impact in the field of Oncology and focused on developing & manufacturing generic oncology drugs, addressing the unmet needs of Cancer patients in Pakistan and beyond. The firm claimed that it is adhering to highest international manufacturing standards, designed by international engineering firm & constructed in accordance with guidelines set by regulatory authorities such as the Drug Regulatory Authority of Pakistan (DRAP), the Pharmaceutical Inspection Co-operation Scheme (PIC/s), and World Health Organization's Good Manufacturing Practice (WHO GMP) guidelines. It further claimed that hundreds of patients across Pakistan have benefited from Oncogen's products, marking a significant milestone in the accessibility of quality medication not only in CML patients in fact other cancer subtypes as well.

Office of Chairman Grievances Committee, Mayo Hospital Lahore
14-10-2024

The firm stated that it has identified specific technical points where its submitted did not receive the expected consideration and outlined its concerns in the following points:

1. Regarding Financial Soundness of the Firm the firm claimed that it did not receive marks for this parameter despite submitting all necessary documentation, including financial statements and a Clander year 2024 FBR returns documents that were attached with the bidding documents. The firm added that it has transitioned its reporting from a financial to a calendar year (affidavit already provided), and have provided monthly sales returns submitted to the FBR, demonstrating sales exceeding 500 million. We have attached relevant documents for your reference and kindly request a reconsideration of this point, awarding the appropriate 5 marks.
2. Regarding Financial Soundness of the Firm the firm claimed that it did not receive marks for this parameter despite submitting all necessary documentation, including financial statements and a Clander year 2024 FBR returns documents that were attached with the bidding documents. The firm added that it has transitioned its reporting from a financial to a calendar year (affidavit already provided), and have provided monthly sales returns submitted to the FBR, demonstrating sales exceeding 500 million. The firm claimed to have attached relevant documents for reference and requested a reconsideration of this point, awarding the appropriate 5 marks.
3. Regarding approval of Oncogen Product Samples the firm stated that the samples submitted for Oncogen products were not approved. The firm urged to reconsider this point, as the samples were provided in accordance with the required specification and have already been qualified and purchased in various government tenders.
4. Regarding Non-Compliance in Compulsory Parameter (Clause 5) with the reason cited for non-responsiveness relates to the DRAP registration experience being less than one year. The firm claimed

that Imatigliv and Nilotinib have completed their one-year registration during the tender process, well before the announcement of the technical evaluation. The firm requested to declare Oncogen Pharma responsive, fostering a healthy competitive and transparent tender process.

Lastly, the firm stated that a thorough reconsideration of these points will reflect the true standing of its submission and promote fairness in the evaluation process.

Decision:

Mr.Iftikhar, Head of Access and Poilicy of M/S Oncogen pleaded the case before the grievances committee. The committee observed that the Technical Evaluation Committee has disqualified the bid due to failure in clause (5) of compulsory parameters and less marks in Ordinary Parameters. The firm then claimed that the one year post registration time has completed during the Technical Evaluation Process. The committee observed that the said requirement was not completed at the time of Tender Opening as the letter of registration has been issued on 21st September 2023, and **decided to uphold the decision of Technical Evaluation Committee in clause (5) of compulsory parameters.** The firm's representative showed Sales Tax Return for the period January 2024 to July 2024 showing turnover amounting to Rs. 174.7 million. **The committee upheld the decision of TEC in section 2 of Ordinary Parameters.** The committee then observed that the sample submitted by the firm qualifies the requirement of clause 7 of compulsory parameters and **decided to declare samples responsive.**

ITEM NO. 02: **GRIEVANCE SUBMITTED BY M/S PHARMASOL (TENDER: CML 2024-25)**

GRIEVANCE DETAIL: The firm submitted the grievance that it participated in the tender (CML-01) 2024-25 against the products i.e. Tab/Cap Imatinib 100mg and Tab/Cap Nilotinib 200mg. The firm stated that its both products have been declared Non-Responsive by the TEC.

1. Regarding Non-Compliance in Compulsory Parameter, Clause 6, the firm submitted that its products Imatinib and Nilotinib are manufactured from FDA approved source as per the requirement of the bidding documents, which can be verified on FDA website for which the papers are submitted. EQDM is European Directorate of Quality Medicine and Health Care having valid approval of both products Imatinib and Nilotinib.
2. Regarding Ordinary Parameters (Source of API), the firm stated that TEC awarded zero marks in Source of API but the firm claims full marks in this parameter as it had submitted Airway Bill / Bill of Lading / GD Documents for ready reference please. The firm added that these documents are also verifiable online through relevant websites and requested to award full marks in this clause.
3. Regarding Ordinary Parameters Clause 9, the firm claimed that it is submitting import documents and COA for Primary reference standard for perusal and requested marks in this parameter as well.
4. Regarding Sample Status the firm submitted that it had submitted samples as per the requirements of the tender but the samples have been declared Not-Responsive by the evaluation committee without giving any sound justification for the rejection of the submitted samples. The firm added that the submitted samples meet the advertised specifications of bidding documents as reflected in the TER but evaluation committee unjustly rejected the samples. Picture attached from TER for your ready reference please.The firm claimed that its quoted products have never been declared Sub-Standard by any Drug Testing Laboratory of the Punjab and requested to accept its samples for healthy and wider competition.

Lastly, the firm requested to consider its plea and marks its products as responsive for healthy competition

Decision: Mr.Irfan, Business Unit Head and Mr. Bahadur, Liaison Officer of M/S Pharmasol pleaded the case before the grievances committee. The committee observed that the Technical Evaluation Committee has

disqualified the bid due to failure in clause (6) of Compulsory Parameters. The firm's representative claimed that the API sources of Imatinib and Nilotinib are FDA approved. The firm first showed reference of FDA Orange book to demonstrate that the finished product of M/S Qilu Pharmaceuticals China is FDA approved. The firm then stated that the name of Qilu Pharmaceutical has been changed to Shandong Anxin Pharmaceutical and presented an FDA inspection report that clearly mentioned that the Shandong Anxin Pharmaceutical China is the subsidiary company of Qilu Pharmaceutical China. It was further mentioned that the company changed name from Qilu Pharmaceutical Eastern Plant to Shandong Anxin Pharmaceutical Company. It was also mentioned that Shandong Anxin Pharmaceutical located in Shandong China is a shared campus comprising of two subsidiary companies The four subsidiary companies mentioned in the report includes Shanding Anxin Laoling Site, Shandong Anxin Dongia Site, Shandong Anshun Pharmaceutical & Qilu Pharmaceutical. To check this the website of Shandong Anxin was accessed and it was mentioned that Shandong Anxin Pharmaceutical Co., Ltd. is one of the subsidiaries of Qilu Pharmaceutical Group. Then the firm claimed to have purchased API Imatinib from M/S Shandong Anxin Pharmaceutical and showed a GD document that showed that the raw material has been purchase from Hexia Pharmaceutical Hongkong that did not contain detail of actual source of Raw Material. However, the firm matched the Batch No. mentioned on the GD with the illegible Airway Bill that also contained name of manufacturer Shandong Anxin Pharmaceutical China. The firm then showed list of Drug Master Files (DMFs) containing the names of Shandong Anxin Pharmaceutical China for Imatinib Mesylate and Shandong Lixin Pharmaceutical for Nilotinib Hydrochloride. Monohydrate. The committee observed that Drug master files (DMFs) are submissions to FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. FDA reviews the technical contents of DMFs in connection with the review of applications that

reference them (e.g., NDAs, ANDAs, INDs, BLAs). The committee observed that inclusion in DMFs is not considered an FDA approval. The firm then claimed to have EMA approval for Nilotinib and submitted a Certificate of Suitability No. RO-CEP 2021-133-Rev 00 issued by European Directorate for the Quality of Medicines & Healthcare in favor of M/S Shandong Lixin Pharmaceutical China. The committee observed that manufacturers or suppliers, or their duly authorised representatives, of active substances or excipients (organic or inorganic, obtained by synthesis, extraction or fermentation), of products with a risk of TSE, or of herbal products used in the production or preparation of pharmaceutical products can apply for CEPs concerning: the evaluation of the suitability of the monograph for the control of the chemical purity and microbiological quality of their substance, the evaluation of the reduction of a risk of TSE, and the evaluation of the suitability of the monograph for the control of herbal drugs and herbal drug preparations. The Certificate of Suitability does not mean the API has EMA approval. The committee then fetched the data from EMA website and found that the Nilotinib of M/S Shandong Lixin has not been authorized/ approved by EMA. **The committee decided to uphold the decision of Technical Evaluation Committee to the extent of clause 6 of Compulsory Parameters for both Imatinib and Nilotinib quoted by M/S Pharmasol**. The firm also claimed points in section 1 of Ordinary Parameters. The committee observed that the API source is not USFDA/ EMA/WHO approved but the firm has provided certificates of analysis for Imatinib Mesylate issued by M/S Shandong Anxin Pharmaceutical China and for Nilotinib Hydrochloride Monohydrate issued by M/S Shandong Lixin Pharmaceutical China. **The committee awarded 5 marks in section 1(B) of ordinary parameters making total 55 marks for both quoted items in Ordinary parameters. However the Nilotinib carries 50 marks due to deduction of marks in grievance submitted by M/S Himmel Pharma.** The firm then claimed that its quoted samples match the advertised specifications. **The committee decided to declare quoted Samples Responsive** as samples qualified the requirements of clause

7 of compulsory parameters. The firm then claimed marks in section 9 of Ordinary Parameters. The firm documents for procurement of Imatinib Reference standard having Catalogue Code Y0001691 form Central Chemicals Lahore along with a GD that showed import of Imatinib from Conseil De L Europe EQDM that was accepted and the **committee also awarded 2 marks in section 9 of Ordinary parameters for Imatinib making total 57 marks in ordinary parameters for Imatinib.** The firm shared GD for Nilotinib that did not contain details of Exporter and Importer, the packing slip issued by US Pharmacopeial Convention also had hidden details of company names and was regretted. **In conclusion the firm remained non-responsive due to failure in clause 6 of compulsory parameters.**

ITEM NO. 03: **GRIEVANCE SUBMITTED BY M/S HIMMEL (TENDER: CML 2024-25)**

GRIEVANCE DETAIL: The firm submitted the grievance that the firm has not been awarded marks against the Serial Number 05 of Ordinary Parameters (Local Market Business). The firm claimed that its quoted product NILOTINIB (NILONIX) 200MG is being marketed in Pakistan for more than two years and as per criteria is eligible for 10 marks. The firm added that at the time of tender submission all the supporting documents were attached with the bidding documents. However all these documents are being attached once again with the grievance letter.

GRIEVENCE AGAINST FIRM ONCOGEN

The firm claimed that the quoted product NILOTINIB 200MG of M/s Oncogen have been awarded 03 marks against Sub Clause D in the Serial number 04 of Ordinary Parameters which state that Experience of The Quoted Product For Last 2 Years should be atleast 25% to below 50% Of Advertised quantity In Public Sector. The firm stated that Firstly, the DRAP registration of quoted product of firm Oncogen have not completed one year and as the criteria demands 2-year experience so Nilotinib does not qualify for this criterion. Secondly, as per market feedback/information the firm Oncogen have not supplied the desired quantity of this product to any public sector Hospital.

GRIEVENCE AGAINST FIRM PHARMASOL

The firm claimed that the quoted product NILOTINIB 200MG of M/s Pharmasol have been awarded 05 marks against Sub Clause C in the Serial number 04 of Ordinary Parameters which states Experience of The Quoted Product for Last 2 Years should be atleast 50% To Below 70% Of Advertised quantity In Public Sector. The firm claimed that as per market feedback/information Pharmasol have not supplied the desired quantity of this product to any public sector Hospital. The firm requested to re-evaluate the bidding documents of Oncogen & Pharmasol against this clause.

Decision:

Dr. Usman, Director Sales & Marketing and Mr. Imtiaz Institutional Deputy General Manager of M/S Himmel Pharma pleaded the case before the grievances committee. The firm's representative stated that the TEC has awarded 0 mark in section (5) of ordinary parameters. He presented an Invoice No. 4935 dated 15.7.2022 for supply of Nilotinib to Alhamd Distributors Rawalpindi and an Invoice No. 4948 dated 15.7.2022 to supply Nilotinib to M/S Rizwan Medicine Company Multan. **The committee awarded 5 marks in section 5 of Ordinary parameters making total score 50 in ordinary parameters.**

GRIEVENCE AGAINST M/S ONCOGEN

The petitioner claimed that TEC has awarded 3 marks to Nilotinib in section 4 of ordinary parameters while the firm does not qualify the requirements of section 4 (D) of ordinary parameters. The committee observed that M/S Oncogen has attached Purchase order No. Health/TPCP/131 dated 14.05.2024 for supply of 1,075,200 capsules of Nilotninb to Hayatabad Medical Complex Health Department Government of Khyber PakhtunKhuwa. The grievance was regretted.

GRIEVENCE AGAINST M/S PHARMASOL

The petitioner claimed that the TEC has awarded 5 marks to Nilotinib under section 4 (C) of ordinary parameters while the firm does not have experience to supply even 25 % of advertised quantity. The defendant admitted that its

firm has not supplied the said quantity. The committee decided to deduct 5 marks in Ordinary parameters. However the defendant remained responsive in ordinary parameters.

ITEM NO. 04: **GRIEVANCE SUBMITTED BY M/S NOVARTIS (TENDER: CML 2024-25)**

GRIEVANCE DETAIL: The firm submitted the grievance with reference to the Technical Evaluation Report for the purchase of Medicines / Drugs (CML-01) FY 2024-25 against the decision in the technical evaluation report of Himmel Pharmaceuticals Pvt. Ltd., Pharmasol Pvt. Ltd. and Oncogen Pharmaceuticals Pvt. Ltd. for tender item No 2.

Grievance Against Himmel Pharmaceuticals Pvt. Ltd

The firm claimed that Tasigna is Patented product of Novartis Pharma Pakistan Limited. Five patents were registered for this product with Nos. 142072, 142073, 142172, 143645, 143724 with the latest patent expiring on 17 Nov 2029. It is with reference to the temporary injunction order for the patent of Nilotinib Hydrochloride based on patent numbers 142172 and 143645 .It is important to mention here that the decisions made regarding the following suit number under order 39 Rules 1 & 2 read with 151 CPC for grant of temporary Injunction in Suit No. 44 / IPT 2024 (Novartis AG versus Himmel Pharmaceuticals Private Limited). Furthermore, we would like to inform you that Novartis instituted legal proceedings against Himmel Pharmaceuticals Pvt. Ltd. for the infringement of patents held by Novartis in Pakistan relating to Nilotinib Hydrochloride Capsules.

Further details on the patent are as follows:

Patent #	Registered	Title
142172	25-April-2016	"A pharmaceutical composition in the form of a capsule comprising a Pyrimidylaminobenzamide Compound"
143645	12-July-2021	

The firm then stated that the presiding officer passed temporary restraining order ("Stay Order") against Himmel Pharmaceuticals Pvt. Ltd. on February 21, 2024 which is valid till date. This stay order restrained Himmel Pharmaceuticals Private Limited from manufacturing, importing, formulating, exporting, marketing, stocking, offering for sale, selling, advertising, participating in public and other procurement tenders or supplying and selling in response to such public and other procurement tenders orders defendant's infringing Nilotinib Hydrochloride Monohydrate capsule product in any Crystalline Form. The order shall cease to have effect unless extended specifically on the next date of hearing. Therefore, for the time being, this firm cannot lawfully manufacture, import, sell and participate in public or other procurement tenders their Nilotinib Hydrochloride Monohydrate capsule product directly or through any distributor.

The firm also stated that it also submitted a letter to CEO, Mayo Hospital Lahore having Dairy Number 14906 Dated 29-08-2024 before the submission of this tender regarding the intimation of temporary injunction order for the patent of Nilotinib Hydrochloride based on patent numbers 142172 and 143645. This letter along with stay order is also attached with the technical bid of Novartis Pharma for the technical evaluation committee.

Copy of this letter is also submitted to the Secretary Specialized Healthcare & Medical Education Department Govt. of Punjab, Lahore, The Chief Drug Controller, Punjab and the Managing Director, PPRA Lahore.

Keeping in view the above facts the firm stated that it is aggrieved of the decision made in the Technical Evaluation Committee regarding the Passing of Product Nilotinib quoted by Himmel Pharmaceuticals Pvt. Ltd. As the presiding officer passed temporary restraining order ("Stay Order") against Himmel Pharmaceuticals Pvt. Ltd. on February 21, 2024 which is valid till date and next date of hearing is 10-10-2024.Therefore, for the time being, this firm cannot lawfully manufacture, import, sell and participate in public or other procurement tenders their Nilotinib Hydrochloride Monohydrate capsule

product directly or through any distributor. Hence the firm Himmel Pharmaceuticals Pvt. Ltd. should be disqualified for this product.

Grievance Against Pharmasol Pvt. Ltd.

The firm stated that Tasigna is Patented product of Novartis Pharma Pakistan Limited. Five patents were registered for this product with Nos. 142072, 142073, 142172, 143645, 143724 with the latest patent expiring on 17 Nov 2029. It is with reference to the temporary injunction order for the patent of Nilotinib Hydrochloride based on patent numbers 142172 and 143645. It is important to mention here that the decisions made regarding the following suit number under order 39 Rules 1 & 2 read with 151 CPC for grant of temporary Injunction in Suit No. 87 / IPT 2024 Novartis AG versus Pharmasol Private Limited. The firm added that it instituted legal proceedings against Pharmasol Pvt. Ltd. for the infringement of patents held by Novartis in Pakistan relating to Nilotinib Hydrochloride Capsules for which the details are as follows:

Patent #	Registered	Title
142172	25-April-2016	"A pharmaceutical composition in the form of a capsule comprising a Pyrimidylaminobenzamide Compound"
143645	12-July- 2021	

The firm added that the presiding officer passed temporary restraining order ("Stay Order") against Pharmasol Pvt. Ltd. on March 28, 2024 which is valid till date. This stay order restrained Pharmasol Private Limited from manufacturing, importing, formulating, exporting, marketing, stocking, offering for sale, selling, advertising, participating in public and other procurement tenders or supplying and selling in response to such public and other procurement tenders orders defendant's infringing Nilotinib Hydrochloride Monohydrate capsule product in any Crystalline Form. The order shall cease to have effect unless extended specifically on the next date

of hearing. Therefore, for the time being, this firm cannot lawfully manufacture, sell and participate in public or other procurement tenders their Nilotinib Hydrochloride Monohydrate capsule product directly or through any distributor. The firm further stated that it also submitted a letter to CEO, Mayo Hospital Lahore having Dairy Number 14906 Dated 29-08-2024 before the submission of this tender regarding the intimation of temporary injunction order for the patent of Nilotinib Hydrochloride based on patent numbers 142172 and 143645. This letter along with stay order is also attached with the technical bid of Novartis Pharma for the technical evaluation committee. Copy of this letter is also submitted to the Secretary Specialized Healthcare & Medical Education Department Govt. of Punjab, Lahore, the Chief Drug Controller, Punjab, and the Managing Director, PPRA Lahore.

Although the Nilotinib 200 mg of Pharmasol is not responsive due to non-compliance in compulsory parameter clause 6 as per announcement of technical evaluation report. Keeping in view the above facts the firm requested that any grievance submitted by the Pharmasol Pvt. Ltd. for reconsideration their Nilotinib product should not be considered at this time based on the decision of stay order against them for the infringement of patent of Nilotinib.

Grievance Against Oncogen Pharmaceuticals Pvt. Ltd.

The firm claimed that Tasigna is Patented product of Novartis Pharma Pakistan Limited. Five patents ware registered for this product with Nos. 142072, 142073, 142172, 143645, 143724 with the latest patent expiring on 17 Nov 2029. It is important to mention here that the decisions made regarding the following suit number under order 39 Rules 1 & 2 read with 151 CPC for grant of temporary Injunction in Suit No. 86 / IPT 2024 (Novartis AG versus Oncogen Pharmaceuticals Private Limited. The firm added that it instituted legal proceedings against Oncogen Pharmaceuticals Pvt. Ltd. for the infringement of patents held by Novartis in Pakistan relating to Nilotinib Hydrochloride Capsules, the details of which are as follows:

Patent #	Registered	Title
142172	25-April-2016	"A pharmaceutical composition in the form of a capsule comprising a Pyrimidylaminobenzamide Compound"
143645	12-July-2021	

The firm added that the presiding officer passed temporary restraining order ("Stay Order") against Oncogen Pharmaceuticals Pvt. Ltd. on March 28, 2024 which is valid till date. This stay order restrain Oncogen Pharmaceuticals Private Limited from manufacturing, importing, formulating, exporting, marketing, stocking, offering for sale, selling, advertising, participating in public and other procurement tenders or supplying and selling in response to such public and other procurement tenders orders defendant's infringing Nilotinib Hydrochloride Monohydrate capsule product in any Crystalline Form. The order shall cease to have effect unless extended specifically on the next date of hearing. Therefore, for the time being, this firm cannot lawfully manufacture, sell and participate in public or other procurement tenders their Nilotinib Hydrochloride Monohydrate capsule product directly or through any distributor.

The firm added that Novartis Pharma (Pakistan) Limited also submitted a letter to CEO, Mayo Hospital Lahore having Dairy Number 14906 Dated 29-08-2024 before the submission of this tender regarding the intimation of temporary injunction order for the patent of Nilotinib Hydrochloride based on patent numbers 142172 and 143645. This letter along with stay order is also attached with the technical bid of Novartis Pharma for the technical evaluation committee. The copy of this letter is also submitted to the Secretary Specialized Healthcare & Medical Education Department Govt. of Punjab, Lahore, the Chief Drug Controller, Punjab, and the Managing Director, PPRA Lahore.

The firm further stated that although the Nilotinib 200 mg of Oncogen is not responsive due to non- compliance in compulsory parameter clause 5 as per DRAP registration according to the announcement of technical evaluation report. Keeping in view the above facts any grievance submitted by the

Oncogen Pharmaceuticals Pvt. Ltd. for reconsideration their Nilotinib product should not be considered at this time based on the decision of stay order against them for the infringement of patent of Nilotinib.

Decision:

Mr. Jawad Malik, Head of KAM, Mr. Mehmood Key Accounts Manager along with counsels presented the grievance on behalf of M/S Novartis Pakistan. The petitioners presented the above stated grievance and presented a Suit for grant of perpetual injunction to restrain the defendant from committing any infringement and/ or counterfeiting and/or imitation of Plaintiff's right in its Patnet No. 142172 and 143645 and for damages etc before the Honorable Intellectual Property Tribunal Punjab Lahore, whereas Honorable court has issued directions that written statements and reply to injunction petition has not been filed and learned counsel for defendant has requested for an adjournment. As per request the case is adjourned to 02.11.2024. It has also been mentioned by the Honorable Court that Ad-interim injunction order already granted is extended.

The representative of Himmel Pharma stated that DRAP Islamabad has given them marketing authorization to import and market Nilotinib in the territory of Pakistan. He further added that The Honorable Court has not decided the case. The representative of M/S Oncogen Pharma presented a document titled "MPP signs license agreement to increase access to Nilotinib for the treatment of Chronic Myeloid Leukemia" and stated that it has been mentioned that through this agreement selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of nilotinib in licensed territory subject to local authorization. In particular the license includes seven middle-income countries including Pakistan.

The committee observed that the final decision of the Honorable Court has not been announced and it is not possible to determine the outcome at this time. The committee decided to regret the grievance with the note that in future the Procuring Agency will proceed with the directions of the Honorable Court once announced.

Office of Chairman Grievances Committee, Mayo Hospital Lahore
14-10-2024

MINUTES OF GRIEVANCES MEETING

MAYO HOSPITAL LAHORE

The meeting ended with vote of thanks to and by the Chair.

Mr. Muhammad Jawad Bhatti
Deputy Drugs Controller
Mayo Hospital Lahore

Mr. Azeem Butt
Deputy Drugs Controller
Mayo Hospital Lahore

Dr. Sana Farooq
Senior Registrar Neurology Dept.
Mayo Hospital Lahore

Dr. Umar Nazir
Assistant Professor Plastic Surgery
Mayo Hospital Lahore

Dr. Nasir Chaudhary
HoD Ophthalmology Department
Mayo Hospital Lahore

AMS (D) Uploaded As Per Policy
17/10/24